Brigatinib Manufacturer List: Takeda, Lonza & 72+ API Suppliers

If you’re searching for a brigatinib manufacturer, you’re likely not a patient. You’re probably a pharmaceutical buyer, a generic drug developer, or someone trying to source this ALK inhibitor for a project. And you’ve probably run into the same problem I did: lots of clinical info, very little about who actually makes the API or the finished drug.

Let me fix that for you. This guide will walk you through the entire supply chain—from the original brand manufacturer to the global network of API suppliers—and help you understand what to look for when choosing a brigatinib manufacturer for your development needs.

First, Why All the Interest in Brigatinib Right Now?

Before we dive into manufacturing, here’s the backstory that’s driving demand. On December 26, 2025, the FDA approved brigatinib (brand name Alunbrig®) as a first-line treatment for ALK-positive metastatic non-small cell lung cancer (NSCLC). That means more patients will be on it, for longer.

More patients mean more pills. More pills mean more demand for API and more reason for any brigatinib manufacturer to scale up production.

The approval was based on solid data from the ALTA-1L trial. Brigatinib cut the risk of disease progression or death by 51% compared to the older drug crizotinib. For patients whose cancer had spread to the brain—a common problem with this disease—the benefit was even bigger.

So yes, brigatinib is having a moment. And that moment is driving a lot of sourcing interest—and a lot of questions about which brigatinib manufacturer to trust.

So Who Actually Is the Original Brigatinib Manufacturer?

Let me walk you through the supply chain, layer by layer.

The Brand Owner: Takeda Pharmaceuticals

Brigatinib was originally developed by a company called ARIAD Pharmaceuticals. Takeda bought ARIAD in 2017—the same year brigatinib got its first FDA approval. Takeda now holds the New Drug Application (NDA) and markets Alunbrig globally. So if you’re asking for the original brigatinib manufacturer in the brand sense, that’s Takeda.

But here’s the thing. Takeda doesn’t make it all in-house. Like most big pharma companies, they outsource a lot of the actual manufacturing to specialized partners. That means there are multiple qualified brigatinib manufacturer entities in the supply chain.

The Key Contract Manufacturing Partner: Lonza

If you trace brigatinib’s manufacturing history, one name keeps coming up: Lonza. This Swiss CDMO (contract development and manufacturing organization) has been Takeda’s partner on brigatinib from early development all the way through commercial production. Lonza is, in effect, a key brigatinib manufacturer for the branded product.

Lonza’s Tampa, Florida facility did the heavy lifting:

• Supported IND and IMPD approvals

• Developed formulations for multiple tablet strengths

• Produced clinical trial material for Phase 1, 2, and 3 studies

• Currently holds EU GMP certificates for commercial manufacturing

As Lonza’s team put it publicly: “As Takeda’s partner for the development and manufacture of ALUNBRIG, we are playing a role in helping to bring this oncology drug to the patients who need it.”

Other Contract Manufacturers

Takeda also works with other CMOs for formulation and packaging. PCI partnered with Takeda for the commercial launch, using PCI’s contained facility designed for potent molecules.

Takeda also has formulation hubs in India and Ireland that specialize in small-molecule oral solids. So the list of brigatinib manufacturer entities extends beyond just one name.

The API Supply Chain: Where the Active Ingredient Comes From

Now let’s get to what you probably really care about: the API itself. Who makes the raw active ingredient? If you’re looking for an API-level brigatinib manufacturer, the landscape looks different.

According to DrugPatentWatch, over 72 bulk API vendors are listed for brigatinib globally. That’s right — more than 72 potential suppliers are already preparing or actively manufacturing brigatinib API, even before the US patent expires.

This tells you two things: competition is real, and if you’re looking for a brigatinib manufacturer, you have plenty of options to evaluate.

Most brigatinib API production happens in China and India. Why? Cost advantages and deep expertise in kinase inhibitors—a class of cancer drugs that includes brigatinib, alectinib, and lorlatinib.

Key players in the ALK inhibitor space include Pfizer, Novartis, Roche, Takeda, Betta Pharmaceuticals, Qilu Pharmaceutical, Jiangsu Aosaikang, and Natco Pharma.

When Can Generic Brigatinib Actually Launch?

This is the million-dollar question. The answer depends on where you’re selling—and it directly affects which brigatinib manufacturer you should consider.

The US composition-of-matter patent (US10385078) doesn’t expire until November 10, 2035. That’s the main barrier for the US market. But China and Japan? Their core patents expired in March 2026.

That means generic development in those markets is already happening—right now. And that means any brigatinib manufacturer based in Asia has a head start.

What This Means for You When Choosing a Brigatinib Manufacturer

If you’re sourcing brigatinib API or intermediates, here’s what I’d keep in mind:

1. Don’t wait for the US market unless you have deep pockets. The 2035 expiry is real. Focus on Asia if you want earlier entry. That means your brigatinib manufacturer should ideally be located in China or India.

2. Choose a partner with TKI experience. Brigatinib is a multi-kinase inhibitor. It’s not a simple molecule to make. You want a bratinib manufacturer who’s done this before—someone who understands kinase inhibitor impurity control and process validation.
3. Verify cGMP compliance. Check for DMF filings, audit history, and impurity control data before committing. A reliable brigatinib manufacturer will provide these documents without hesitation.
4. Consider China-based suppliers. With the patent already expired there, Chinese manufacturers are actively developing processes. They’re ready to supply for Asian markets. If you need a brigatinib manufacturer for early development or regional launch, China is your best bet right now.

A Note on Our Capabilities

At Tianming Pharmaceutical, we are a brigatinib manufacturer of high-purity intermediates and APIs for targeted oncology drugs, including ALK inhibitors. We’ve been tracking the brigatinib patent landscape closely—especially the March 2026 expiry in China and Japan.

As more generic opportunities open up, having a reliable supply partner with TKI manufacturing experience will make all the difference.

If you’re developing brigatinib generics or need a sourcing partner for ALK inhibitor intermediates, we’d welcome the conversation. Technical specifications, impurity profiles, and DMF support are available upon request.

At Tianming Pharmaceutical, we supply high-purity brigatinib intermediates and APIs. For technical data or to discuss your project, contact our team. sunqian0123@gmail.com